Aclidinium

Also known as: Aclidinium bromide

Active ingredient description

Aclidinium is a competitive, selective muscarinic receptor antagonist (also known as an anticholinergic), with a longer residence time at the M3 receptors than the M2 receptors. M3 receptors mediate contraction of airway smooth muscle. Inhaled aclidinium acts locally in the lungs to antagonise M3 receptors of airway smooth muscle and induce bronchodilation.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
R03BB05
R Respiratory system → R03 Drugs for obstructive airway diseases → R03B Other drugs for obstructive airway diseases, inhalants → R03BB Anticholinergics
Discover more medicines within R03BB05

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
BRETARIS GENUAIR Inhalation powder
Summary of Product Characteristics (SPC)

Medicines

Aclidinium is the active ingredient of these drugs:

Drug
Countries
BRETARIS GENUAIR

Australia Austria Estonia Ireland Lithuania

EKLIRA GENUAIR

Austria Cyprus Estonia Finland Hong Kong

RISBRETA GENUAIR

Turkey

TUDORZA GENUAIR

Canada

TUDORZA PRESSAIR

United States

Aclidinium is also found within below combination drugs:

BRIMICA , DUAKLIR

Structural formula

Graphic representation of the active ingredient's molecular structure

Chemical formula: C₂₆H₃₀BrNO₄S₂
Molecular mass: 484.651 g/mol

External identifiers

CAS Substance: 320345-99-1
DrugBank Drug: DB08897
KEGG Drug: D08837
PubChem Compound: 11434515
RxNorm Ingredient: 1303097
SNOMED-CT Concept: 703921008
Aclidinium (substance)
UNII Identifier: K17VY42F6C
ACLIDINIUM
 
Next: Usage >